Haematologica, Vol 92, Issue 3, 401-404 doi:10.3324/haematol.10822
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soverini, S.
Right arrow Articles by Martinelli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soverini, S.
Right arrow Articles by Martinelli, G.

Chronic Myeloid Leukemia

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Simona Soverini, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Gianantonio Rosti, Costanza Bosi, Stefania Paolini, Michela Rondoni, Pier Paolo Piccaluga, Francesca Palandri, Panagiota Giannoulia, Giulia Marzocchi, Simona Luatti, Nicoletta Testoni, Ilaria Iacobucci, Daniela Cilloni, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli

From the Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy (SS, SC, AG, FC, GR, CB, SP, MR, PPP, FP, PG, GM, SL, NT, II, MB, GM); Department of Clinical and Biological Science, University of Turin, Orbassano, Italy (DC, GS).

Correspondence: Giovanni Martinelli, MD, Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", S. Orsola-Malpighi Hospital, Massarenti 9, 40138 Bologna, Italy. E-mail: gmarti-no{at}kaiser.alma.unibo.it

The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) leukemia has prompted the development of second-generation compounds active against several imatinib-insensitive mutant forms of Bcr-Abl, including dasatinib (BMS-354825; Bristol-Myers Squibb). In order to assess which pre-existent or emerging kinase domain mutations are associated with decreased clinical efficacy of desatinib, we analyzed BCR-ABL kinase sequences before and during treatment in 21 Ph+ patients who failed to respond to or relapsed during dasatinib therapy. In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317.

Key words: chronic myeloid leukemia, acute lymphoblastic leukemia, imatinib, dasatinib, resistance, Bcr-Abl, mutations.




This article has been cited by other articles:


Home page
BloodHome page
S. Branford, J. V. Melo, and T. P. Hughes
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Blood, December 24, 2009; 114(27): 5426 - 5435.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. E. Nicolini, M. J. Mauro, G. Martinelli, D.-W. Kim, S. Soverini, M. C. Muller, A. Hochhaus, J. Cortes, C. Chuah, I. H. Dufva, et al.
Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
Blood, December 17, 2009; 114(26): 5271 - 5278.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, et al.
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
J. Clin. Oncol., December 10, 2009; 27(35): 6041 - 6051.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. P. Shah
Fine-tuning targeted therapy of CML
Blood, December 3, 2009; 114(24): 4914 - 4915.
[Full Text] [PDF]


Home page
BloodHome page
M. C. Muller, J. E. Cortes, D.-W. Kim, B. J. Druker, P. Erben, R. Pasquini, S. Branford, T. P. Hughes, J. P. Radich, L. Ploughman, et al.
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Blood, December 3, 2009; 114(24): 4944 - 4953.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Hughes, G. Saglio, S. Branford, S. Soverini, D.-W. Kim, M. C. Muller, G. Martinelli, J. Cortes, L. Beppu, E. Gottardi, et al.
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
J. Clin. Oncol., September 1, 2009; 27(25): 4204 - 4210.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
T. Ernst, F. X. Gruber, O. Pelz-Ackermann, J. Maier, M. Pfirrmann, M. C. Muller, I. Mikkola, K. Porkka, D. Niederwieser, A. Hochhaus, et al.
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
Haematologica, September 1, 2009; 94(9): 1227 - 1235.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
E. Jabbour, J. E. Cortes, and H. M. Kantarjian
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
O. G. Ottmann and H. Pfeifer
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
Hematology, January 1, 2009; 2009(1): 371 - 381.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
D. Bixby and M. Talpaz
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
Hematology, January 1, 2009; 2009(1): 461 - 476.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Jabbour, H. M. Kantarjian, D. Jones, N. Reddy, S. O'Brien, G. Garcia-Manero, J. Burger, and J. Cortes
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
Blood, December 15, 2008; 112(13): 4839 - 4842.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. W. Deininger
Nilotinib
Clin. Cancer Res., July 1, 2008; 14(13): 4027 - 4031.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, et al.
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib
PNAS, April 8, 2008; 105(14): 5507 - 5512.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
L. K. Kenealy, C. B. Christenson, and C. B. Williams
Current Therapies for Chronic Myeloid Leukemia
Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125.
[Abstract] [PDF]


Home page
BloodHome page
J. S. Khorashad, D. Milojkovic, P. Mehta, M. Anand, S. Ghorashian, A. G. Reid, V. De Melo, A. Babb, H. de Lavallade, E. Olavarria, et al.
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
Blood, February 15, 2008; 111(4): 2378 - 2381.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood, October 15, 2007; 110(8): 2828 - 2837.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. O'Hare, C. A. Eide, and M. W. N. Deininger
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Blood, October 1, 2007; 110(7): 2242 - 2249.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
S. Soverini, I. Iacobucci, M. Baccarani, and G. Martinelli
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias
Haematologica, April 1, 2007; 92(4): 437 - 439.
[Full Text] [PDF]


Home page
ASH Education BookHome page
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology, January 1, 2007; 2007(1): 376 - 383.
[Abstract] [Full Text] [PDF]